Fermiscan is working to develop a world-first innovative test for the detection of breast cancer using hair. The breakthrough technology that underpins the Fermiscan™ Test is the discovery by an Australian scientist that breast cancer can potentially be detected by synchrotron x-ray diffraction of hair. The test is non-invasive and suitable for women from as early as 20 years of age. It may provide early detection of breast cancer thus assist in early treatment. Early detection benefits range from increased survival, increased treatment options and improved quality of life. The Fermiscan™ Test is in trial and not yet available commercially.
If you would like more information about Fermiscan Holdings Limited, please contact us using the details below.
Address
Fermiscan Holdings Limited
Level 5
48 Hunter Street
Sydney
NSW 2000
E-mail
If you would like to e-mail us please click here and we will respond back to you as quickly as possible.
